J.P. Morgan Upgrades Covidien (COV) to Overweight
More News related to COV
- Covidien (COV) and Depomed (DEPO) Announce License Agreement
- Covidien and Depomed Announce License Agreement
- Covidien Launches Improved Magellan Safety Hypodermic Needle
- Citi Maintains 'Buy' on Covidien Ltd (COV), Lowers Price Target
- David Moenning's Daily State of the Markets: 11/17
More News related to Upgrades
- Raymond James Starts Millicom (MICC) at Strong Buy
- Stifel Nicolaus Starts City National (CYN) at Hold
- Stifel Nicolaus Starts eHealth (Nasdaq: HLTH) with a Buy
- Wasserman & Associates initiates coverage on American Physicians Service Group (AMPH) with a Buy
- Jesup & Lamont Initiates Coverage on AutoZone (AZO) with a Hold.
J.P. Morgan upgrades Covidien (NYSE: COV) from Neutral to Overweight.
Covidien Ltd. (Covidien) is engaged in the development, manufacture and sale of healthcare products for use in clinical and home settings.
Related Categories
UpgradesStocks Mentioned
+0.81Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
